BIOINVENT INTERNATIONAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.95 SEK | +1.53% |
|
+19.32% | +57.96% |
Presentation Operator MessageOperator (Operator)Hello and welcome to BioInvent Q3 Report 2022....
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Companyâs operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
29.5
SEK
Average target price
83
SEK
Spread / Average Target
+181.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +57.96% | 181M | |
| +8.85% | 114B | |
| +11.47% | 104B | |
| -12.76% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -3.24% | 17.89B | |
| +8.04% | 14.28B | |
| +34.76% | 12.55B |
- Stock Market
- Equities
- BINV Stock
- News BioInvent International AB
- Transcript : BioInvent International AB, Q3 2022 Earnings Call, Oct 27, 2022